Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Borneol/edaravone - Simcere

Drug Profile

Borneol/edaravone - Simcere

Alternative Names: Compound edaravone; Edaravone combination; Edaravone Dexborneol; Edaravone/borneol; Sanbaxin®; Sanbexin; SIM 071201

Latest Information Update: 22 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroDawn; Simcere Pharmaceutical Group
  • Developer Simcere Pharmaceutical Group
  • Class Antidementias; Heterocyclic bicyclo compounds; Neuroprotectants; Pyrazolones; Small molecules; Terpenes; Vascular disorder therapies
  • Mechanism of Action Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stroke
  • New Molecular Entity No

Highest Development Phases

  • Marketed Stroke
  • Phase II Cerebral haemorrhage
  • No development reported Cerebrovascular disorders

Most Recent Events

  • 18 Mar 2024 Simcere Pharmaceutical plans phase-II trial for Cognition disorders (In adults, In the elderly) in China (Sublingual, Tablet) in March 2024 (NCT06315231),
  • 03 Jul 2023 Phase-II clinical trials in Cerebral haemorrhage (Combination therapy, In adults, In the elderly) in China (Injection) (NCT05953103)
  • 01 Jun 2023 Simcere Pharmaceutical Group plans a phase III EARLYS trial for Stroke in China (Parenteral, Injection) (NCT05885919)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top